Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.60
RMTI's Cash to Debt is ranked higher than
61% of the 922 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. RMTI: 0.60 )
RMTI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.6

Equity to Asset -0.23
RMTI's Equity to Asset is ranked lower than
55% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RMTI: -0.23 )
RMTI' s 10-Year Equity to Asset Range
Min: -0.59   Max: 0.92
Current: -0.23

-0.59
0.92
F-Score: 4
Z-Score: -0.61
M-Score: -2.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -37.36
RMTI's Operating margin (%) is ranked higher than
54% of the 872 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. RMTI: -37.36 )
RMTI' s 10-Year Operating margin (%) Range
Min: -108.87   Max: 2.28
Current: -37.36

-108.87
2.28
Net-margin (%) -43.34
RMTI's Net-margin (%) is ranked higher than
53% of the 872 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.53 vs. RMTI: -43.34 )
RMTI' s 10-Year Net-margin (%) Range
Min: -108.39   Max: 1.18
Current: -43.34

-108.39
1.18
ROA (%) -74.36
RMTI's ROA (%) is ranked lower than
52% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.79 vs. RMTI: -74.36 )
RMTI' s 10-Year ROA (%) Range
Min: -220.66   Max: 2.88
Current: -74.36

-220.66
2.88
ROC (Joel Greenblatt) (%) -1140.56
RMTI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 921 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.01 vs. RMTI: -1140.56 )
RMTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2683.72   Max: 11.55
Current: -1140.56

-2683.72
11.55
Revenue Growth (3Y)(%) -23.00
RMTI's Revenue Growth (3Y)(%) is ranked higher than
52% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. RMTI: -23.00 )
RMTI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23   Max: 36.8
Current: -23

-23
36.8
EBITDA Growth (3Y)(%) 159.60
RMTI's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. RMTI: 159.60 )
RMTI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.2   Max: 159.6
Current: 159.6

-36.2
159.6
EPS Growth (3Y)(%) 109.90
RMTI's EPS Growth (3Y)(%) is ranked higher than
98% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. RMTI: 109.90 )
RMTI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 109.9
Current: 109.9

0
109.9
» RMTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RMTI Guru Trades in

RMTI Guru Trades in

Q2 2013

RMTI Guru Trades in Q2 2013

Jim Simons 185,628 sh (New)
» More
Q3 2013

RMTI Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 12.17
RMTI's Forward P/E is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 60.61 vs. RMTI: 12.17 )
N/A
P/S 7.90
RMTI's P/S is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.96 vs. RMTI: 7.90 )
RMTI' s 10-Year P/S Range
Min: 0.47   Max: 9.87
Current: 7.9

0.47
9.87
EV-to-EBIT -24.58
RMTI's EV-to-EBIT is ranked higher than
61% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.12 vs. RMTI: -24.58 )
RMTI' s 10-Year EV-to-EBIT Range
Min: -431.1   Max: 184.2
Current: -24.58

-431.1
184.2
Current Ratio 1.15
RMTI's Current Ratio is ranked higher than
53% of the 896 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.45 vs. RMTI: 1.15 )
RMTI' s 10-Year Current Ratio Range
Min: 0.49   Max: 8.6
Current: 1.15

0.49
8.6
Quick Ratio 0.98
RMTI's Quick Ratio is ranked higher than
57% of the 896 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. RMTI: 0.98 )
RMTI' s 10-Year Quick Ratio Range
Min: 0.35   Max: 8
Current: 0.98

0.35
8
Days Inventory 22.84
RMTI's Days Inventory is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.90 vs. RMTI: 22.84 )
RMTI' s 10-Year Days Inventory Range
Min: 18.25   Max: 46.23
Current: 22.84

18.25
46.23
Days Sales Outstanding 28.48
RMTI's Days Sales Outstanding is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 96.09 vs. RMTI: 28.48 )
RMTI' s 10-Year Days Sales Outstanding Range
Min: 23.3   Max: 54.67
Current: 28.48

23.3
54.67

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 4.15
RMTI's Price/Median PS Value is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.43 vs. RMTI: 4.15 )
RMTI' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 4.51
Current: 4.15

0.21
4.51
Earnings Yield (Greenblatt) -4.30
RMTI's Earnings Yield (Greenblatt) is ranked higher than
56% of the 923 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RMTI: -4.30 )
RMTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 3.6
Current: -4.3

0.5
3.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RWM.Germany,
Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 
Rockwell Medical Technologies Inc. (RMTI) Vice President, CFO Thomas E Klema sells 15,000 Shares Jan 03 2011 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 07 2010 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 06 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 10 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 11 2009 


More From Other Websites
Should Rockwell Medical (RMTI) Be On Your Radar Now? - Tale of the Tape Feb 27 2015
Rockwell Medical reports 4Q loss Feb 26 2015
Rockwell Medical reports 4Q loss Feb 26 2015
Rockwell Medical Reports Fourth Quarter 2014 Results Feb 26 2015
4:12 pm Rockwell Medical misses by $0.04, beats on revs Feb 26 2015
Rockwell Medical Reports Fourth Quarter 2014 Results Feb 26 2015
Q4 2014 Rockwell Medical Inc Earnings Release - After Market Close Feb 26 2015
Why Earnings Season Could Be Great for Rockwell Medical (RMTI) - Tale of the Tape Feb 24 2015
Rockwell Medical Schedules Fourth Quarter Earnings Call Feb 23 2015
Rockwell Medical Schedules Fourth Quarter Earnings Call Feb 23 2015
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Jan 28 2015
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 27 2015
Brean Predicts 'A Skid And A Crash' For Rockwell Medical's Triferic Drug Jan 26 2015
Rockwell Medical (RMTI) Stock Higher Today After FDA Approves Iron Replacement Drug Jan 26 2015
Why Shares Of Rockwell Medical Are Up Huge Jan 26 2015
U.S. FDA Approves Rockwell's Triferic(TM) for Iron Replacement and Maintenance of Hemoglobin in... Jan 26 2015
FDA approves Rockwell Medical's iron replacement drug Jan 26 2015
U.S. FDA Approves Rockwell's Triferic(TM) for Iron Replacement and Maintenance of Hemoglobin in... Jan 26 2015
NxStage Revises Up 2014 Guidance on Strong Home Growth - Analyst Blog Jan 14 2015
Rockwell Medical Announces Two Triferic Abstracts to be Presented at Annual Dialysis Conference Jan.... Jan 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK